Not Yet Recruiting
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
NCT07332351
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +11 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States